SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information <u>(including phone and fax #s)</u> on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: (Please select drug below)

	`	
	Preferred Medication (must be	tried and failed FIRST)
	Ivabradine (generic Corlanor®)	
	Non-Prefer	red
- (Corlanor® (ivabradine)	
ME	EMBER & PRESCRIBER INFORMATION:	Authorization may be delayed if incomplete.
Memb	aber Name:	
	aber Sentara #:	
Presci	criber Name:	
	criber Signature:	
Office	ce Contact Name:	
	ne Number:	
NPI #	#:	
DRU	UG INFORMATION: Authorization may be dela	yed if incomplete.
Drug !	Name/Form/Strength:	
	ng Schedule:	
Diagn	nosis:	ICD Code, if applicable:
Weigh	ght (if applicable):	Date weight obtained:
suppo	INICAL CRITERIA: Check below all that apply. port each line checked, all documentation, including labyided or request may be denied.	
	Corlanor® is being prescribed by (or in consultation v	with) a cardiologist
	Diagnosis of stable, symptomatic heart failure with L	VEF ≤ 35%
	Member is in sinus rhythm with resting heart rate ≥ 7	0 bpm

(Continued on next page)

PA Ivabradine, Corlanor (Medicaid) (Continued from previous page)

	Member is currently on maximal dose of a β -blocker or has a contraindication to β -blockers e.g., carvedilol, metoprolol (verified by chart notes or pharmacy paid claims)	
	Member's blood pressure is $\geq 90/50 \text{ mmHg}$	
	If requesting brand Corlanor®, documentation of trial and intolerable life-endangering adverse event with generic ivabradine must be submitted	
*:	*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **	
Pre	evious therapies will be verified through pharmacy paid claims or submitted chart notes.*	

^{*}Approved by Pharmacy and Therapeutics Committee: 8/26/2017; 7/21/2022
*REVISED/UPDATED/REFORMATTED: 8/26/2017; 8/17/2018; 1/29/2020;08/12/2022; 11/8/2023; 3/24/2025